Loading...
XSHE
300406
Market cap1.13bUSD
Dec 05, Last price  
13.68CNY
1D
0.66%
1Q
-2.15%
Jan 2017
-37.79%
IPO
141.27%
Name

Beijing Strong Biotechnologies Inc

Chart & Performance

D1W1MN
XSHE:300406 chart
P/E
15.06
P/S
4.83
EPS
0.91
Div Yield, %
1.46%
Shrs. gr., 5y
3.36%
Rev. gr., 5y
14.56%
Revenues
1.66b
-4.75%
275,963,544380,144,035444,625,403508,274,279566,201,720667,402,749694,277,363774,178,200840,861,681848,118,4931,599,384,3521,510,871,8841,741,626,6751,658,931,975
Net income
533m
+1.70%
100,782,568137,009,922180,637,381210,640,919245,043,364271,646,051273,151,407300,665,281331,648,680112,277,109405,651,172389,097,640523,742,821532,635,347
CFO
614m
+4.04%
45,898,334125,486,142147,193,672156,938,955142,586,445243,206,450207,907,483256,147,805188,603,373123,058,597341,098,641396,165,883590,149,292614,011,929
Dividend
May 07, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Strong Biotechnologies, Inc. provides in-vitro diagnostics products and services in the People's Republic of China and internationally. It offers clinical biochemistry products, such as reagents and automatic biochemistry analyzers; coagulation products, including reagents and automated coagulation analyzers; and serology products comprising blood type test cards and automated blood grouping analyzers. The company was founded in 2001 and is headquartered in Beijing, the People's Republic of China.
IPO date
Oct 30, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT